three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: melittin, apamin and mastoparan

Clicks: 263
ID: 185964
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #144 of 300 articles by views in matec web of conferences

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 300 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
While knowledge of the composition and mode of action of bee and wasp venoms dates back 50 years, the therapeutic value of these toxins remains relatively unexploded. The properties of these venoms are now being studied with the aim to design and develop new therapeutic drugs. Far from evaluating the extensive number of monographs, journals and books related to bee and wasp venoms and the therapeutic effect of these toxins in numerous diseases, the following review focuses on the three most characterized peptides, namely melittin, apamin, and mastoparan. Here, we update information related to these compounds from the perspective of applied science and discuss their potential therapeutic and biotechnological applications in biomedicine.
Reference Key
moreno2015toxinsthree Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Miguel Moreno;Ernest Giralt
Journal matec web of conferences
Year 2015
DOI
10.3390/toxins7041126
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.